Baylor College of Medicine (Baylor) has a heritage of more than a century of biomedical research. It is a leading global institution with initiatives that bring basic science, translational, and clinical researchers together across disciplines and specialties to discover fundamental insights into human health and disease.
Founded by Dr Malcolm Brenner, the Center for Cell and Gene Therapy (CAGT) at Baylor comprises laboratories with preclinical, translational, gene vector, and extensive clinical research programs.
St. Jude Children’s Research (St Jude) Hospital leads the way the world understands, treats and cures childhood cancer and other life-threatening diseases, by advancing cures, and means of prevention for paediatric catastrophic diseases through research and treatment.
The goal of the partnership is to explore a new approach to cellular immunotherapy by targeting multiple tumor antigens with CARs using Tessa’s VST platform. This novel multi-CAR VST approach carries the potential to improve survival rates in children as well as reduce the chance of tumor escape, a phenomenon where cancer evolves to evade a successful treatment.
National Cancer Centre Singapore (NCCS) is a national and regional center of excellence in research, education and clinical services, and patient care.
It is the base for the largest number of oncologists, researchers, and clinician-scientists in Singapore, with research widely recognized by the international medical community. The community of onsite research staff work to resolve clinically relevant questions to cancer in Singapore and other countries in the region.
The Agency for Science, Technology and Research (A*STAR) is Singapore’s lead public sector agency that spearheads economic oriented research to advance scientific discovery and develop innovative technology.
As a Science and Technology Organisation, A*STAR bridges the gap between academia and industry, and its research creates economic growth and jobs for Singapore, and enhances lives by contributing to societal benefits such as improving outcomes in healthcare, urban living, and sustainability.
A*STAR oversees 18 biomedical sciences and physical sciences and engineering research entities primarily located in Biopolis and Fusionopolis.
The Parker Institute for Cancer Immunotherapy is an unprecedented collaboration that brings together the best scientists, clinicians and industry partners to build a smarter and more coordinated cancer immunotherapy research effort.
The Parker Institute network includes six research centers, more than 40 industry and nonprofit partners, more than 60 labs and more than 300 of the nation’s top researchers focused on treating the deadliest cancers. The institute’s goal is to accelerate the development of breakthrough immune therapies capable of turning most cancers into curable diseases.
MSD, is a leading global biopharmaceutical company also known as Merck & Co., Inc., Kenilworth, N.J., USA, that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies and animal health products.
Tessa Therapeutics and MSD are collaborating to evaluate Tessa’s armored human papillomavirus-specific T cell (HPVST) therapy, or TT12, in combination with KEYTRUDA® (pembrolizumab), MSD’s anti-PD-1 (programmed death receptor-1) therapy, in patients with recurrent or metastatic HPV 16 and 18-positive cervical cancer.
More on this collaboration
More on MSD
Peking Union Medical College Hospital (PUMCH) is a leading comprehensive hospital in China.
PUMCH and Tessa are working together to accelerate the research and development of next-generation cellular immunotherapies targeting some of the most common cancers in China. Both partners will jointly design and prepare clinical trials to test novel cell therapies, including therapies within Tessa’s clinical pipeline, in China.
What are you looking for?